Genome-wide strategies have driven the discovery of more than 300
susceptibility loci for autoimmune diseases. However, for almost all loci,
understanding of the mechanisms leading to autoimmunity remains limited, and
most variants that are likely to be causal are in non-coding regions of the
genome. A critical next step will be to identify the in vivo
and ex vivo immunophenotypes that are affected by risk
variants. To do this, key cell types and cell states that are implicated in
autoimmune diseases will need to be defined. Functional genomic annotations from
these cell types and states can then be used to resolve candidate genes and
causal variants. Together with longitudinal studies, this approach may yield
pivotal insights into how autoimmunity is triggered.